SCHEMBL12876016

SCHEMBL12876016

CCOC(=O)c1cnn(Cc2nc(-c3cc(C)cc(OC)c3)cs2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.39
MAPT P10636 5/20 0.39
L3MBTL1 Q9Y468 3/20 0.39
RAB9A P51151 3/20 0.39
GRM2 Q14416 1/20 0.39
KDM4E B2RXH2 4/20 0.37
NPC1 O15118 2/20 0.37
HPGD P15428 2/20 0.37
HSP90AA1 P07900 1/20 0.37
GAA P10253 2/20 0.37
AKT1 P31749 1/20 0.37
CNKSR1 Q969H4 1/20 0.37
IDO1 P14902 1/20 0.37
PPARD Q03181 1/20 0.36
PPARA Q07869 1/20 0.36
KLKB1 P03952 1/20 0.36
PTGS2 P35354 2/20 0.36
CYP1A1 P04798 1/20 0.36
CYP1B1 Q16678 1/20 0.36
KMT2A Q03164 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12876017 0.89 MEN1 (0.41) MEN1MAPTL3MBTL1RAB9AKDM4E
SCHEMBL12876118 0.89 GRM2 (0.40) MEN1MAPTL3MBTL1RAB9AGRM2
SCHEMBL1198356 0.88 XPO1 (0.43) MEN1MAPTL3MBTL1RAB9AGRM2
SCHEMBL1198524 0.88 MEN1 (0.52) MEN1MAPTL3MBTL1RAB9AKDM4E
SCHEMBL1199299 0.88 ALDH1A1 (0.45) MEN1MAPTL3MBTL1RAB9AKDM4E
SCHEMBL12875909 0.88 GRM2 (0.39) MEN1MAPTL3MBTL1RAB9AGRM2
SCHEMBL12875801 0.88 GRM2 (0.45) MEN1MAPTL3MBTL1RAB9AGRM2
SCHEMBL12875888 0.88 GRM2 (0.39) MAPTL3MBTL1RAB9AGRM2KDM4E
SCHEMBL12875967 0.87 GRM2 (0.42) MEN1MAPTL3MBTL1RAB9AGRM2
SCHEMBL12875965 0.86 GRM2 (0.40) MEN1MAPTL3MBTL1RAB9AGRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A MEN1 2661/4885MAPT 4667/4885L3MBTL1 4726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.